HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $120
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $110 to $120.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $110 to $120.